Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients
June 9 (Reuters) - Avidity Biosciences Inc RNA.O:
AVIDITY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE PHASE 1/2 FORTITUDE™ DATA DEMONSTRATING CONSISTENT IMPROVEMENT ACROSS MULTIPLE FUNCTIONAL MEASURES COMPARED TO PLACEBO IN DEL-BRAX TREATED FSHD PARTICIPANTS
AVIDITY BIOSCIENCES INC - DATA SUPPORT PLANNED ACCELERATED APPROVAL BLA SUBMISSION IN H2 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Tesla Q1 2026 Earnings Preview: 50,000-Unit Inventory Overhang, Energy Storage Halved, 5 Core Metrics Long-Term Investors Should Really Watch

Asia-Pacific Stocks Rise Across the Board Monday as Easing Middle East Tensions Boost Market Sentiment

AST SpaceMobile Shares Plunge in Overnight Trading, What Happened? Will It Affect SpaceX?

Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

Intel Stock Has Surged 74% in 2026 and Earnings Land April 23 — Is INTC Still a Buy at $68?

Tradingkey






